Keywords
How to Cite
Abstract
We studied ability of TMA technique as alternative to analysis of whole sections (WS) for breast carcinomas. The study included 229 patients with breast carcinoma T1-2 N0 M0 treated within 2000-2009 years. After whole slide scanning were constructed TMA blocks using 2mm punches and TMA master device (3DHistech, Budapest). TMA results of immunohistochemistry of HER2 were compared retrospectively with the results of WS. General distribution of HER2 status for WS was: negative (0+1) 85,5%, unequal (2+) 6,07%, positive (3+) - 8.41%, for TMA cores negative (0+1) 82,6%, unequal (2+) 7,04%, positive (3+) - 10,33%. When we compared each cases for HER2 there was moderate agreement with negative (score 0) and positive(score 3+) case around 70% and poor agreement in HER2 (1+2+ category) - only 50% 25% including both false negative and false positive estimations. We thought such kind disagreement in individual group was due to using different primary antibodies (all not FDA-approved) in previous years compared with PATHWAY® rmAb 4B5 (Ventana) antibody which was used for TMA slides. For breast cancer TMAs could be reasonable alternative to WS. Especially for Her2 testing, should be used only FDA approved systems and this technique allow reduce time, reagent and finally cost of such type of analysis.References
Albanghali M, Green A, Rakha E. at al. Construction of tissue microarrays from core needle biopsies - a systematic literature review. Histopathology. 2015 Aug 12 (epub ahead of print)
Bubendorf L, Kolmer M, Kononen J. at al. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays // J Natl Cancer Inst. - 1999. - Vol. 91. - P. 1758-1764.
Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers // J Clin Oncol. - 2008. - Vol. 34. -P. 5630-5637.
Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma // Lab Invest. - 2000. - Vol. 12. - P. 1943-1949.
Gasljevic G, Lamovec J, Contreras JA. et al. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study // Pathol Oncol Res. - 2013. - Vol. 19. - P. 855-865.
Fitzgibbons P. L., Dillon D, Alsabeh R. et al. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast http:// www.cap.org/apps/docs/committees/cancer/cancer_ protocols/ breast_biomarker_template.pdf
Franco R, Caraglia M, Facchini G et al. The role of tissue microarray in the era of target-based agents // Expert Rev Anticancer Ther. - 2011. - Vol. 6. - P. 859-869.
Kononen J, Bubendorf L, Kallioniemi A. et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens // Nat Med. - 1998. - Vol. 4. - P. 844-847.
Moch H, Schraml P, Bubendorf L High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma // Am J Pathol.- 1999. - Vol. 154. - P. 981-986.
Mucci NR, Akdas G , Manely S. et al.Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression // Hum Pathol. - 2000. - Vol. 31. - P. 406-414.
Perrone EE, Theoharis C, Mucci NR et al. Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men // J Natl Cancer Inst. - 2000. - Vol. 92. - P. 937-939.
Pinder S E, Brown J P, Gillett Ch. et al. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example // J Clin Pathol. - 2013. - Vol. 66 (3) - P. 169-177.
Schraml P, Kononen J, Bubendorf L. Tissue microarrays for gene amplification surveys in many different tumor types // Clin Cancer Res. - 1999. - Vol. 5. - P. 1966-1975.
Voduc D, Kenney K, Nielsen T. Tissue Microarrays in Clinical Oncology // Seminars in radiation oncology. - 2008. - P. 89-97.
Vyberg M, Nielsen S, R ge R Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests // BMC Health Serv Res. - 2015. - Vol. 15. - P. 352.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...